by using Internet-based search engines.
T he survival benefit of internal mammary artery (IMA) grafting in coronary artery bypass grafting (CABG) surgery was described over a quarter of a century ago. 1 Since then, the potential benefits of bilateral internal mammary artery (BIMA) grafting over single internal mammary artery (SIMA) grafting on survival and cardiac-related events have been emphasized by many investigators. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] In 2001, our group published a systematic review including a meta-analysis with 15 962 patients with the BIMA group showing a significant reduction in mortality (hazard ratio, 0·81; 95% confidence interval [CI], 0.70-0.94) after a median of 4 years of follow-up with no study showing significantly harmful effect of BIMA grafts. 2 This benefit is likely to be a consequence of documented patency rates of ≥90% for BIMA grafts into the third decade of follow-up in contrast to vein grafts of which three-quarters are occluded or severely diseased by 10 years of follow-up. 12, 13 Clinical Perspective on p 545
However, BIMA grafting is still not widely accepted by cardiac surgeons, and, currently, <10% of European and <5% of North American patients receive BIMA grafts. 14, 15 Increasing use of BIMA grafting may in due course be influenced by the outcome of an ongoing multicenter, randomized trial comparing survival between SIMA and BIMA grafting, the Arterial Revascularisation Trial (ART), which has enrolled 3102 patients. Interim 1-year outcomes have been reported, but the primary end point of 10-year survival will not be reported until 2018. 16 In this current systematic review and meta-analysis, we aimed to assess whether the use of BIMA grafting has a long-term survival benefit into the second decade after CABG.
The words used for search included "internal mammary (internal thoracic)," "single," "unilateral," "multiple," "bilateral," "artery,", and their combinations using the term "AND." In addition, we searched reference lists of relevant studies, review articles, and meeting abstracts. We included published articles satisfying the following criteria: (1) survival comparison of single and bilateral IMA grafting;
(2) long-term results with more than a mean of 9 years of followup; and (3) minimum 100 patients in each group. If any institution reported ≥2 reports on this issue, the latest one was included. Studies were excluded unless the comparability of patient characteristics was controlled either by design or analysis, at least for age, sex, ventricular function, and diabetes mellitus. Only articles published in English were included.
All data were extracted independently by 2 reviewers (G.Y. and D.T.). If there were any discrepancies, they were resolved by consensus meeting. In studies where hazard ratios were not given directly, we calculated them by using a spreadsheet method for extracting data from published literature provided by Tierney and colleagues. 17 The primary outcome measurement was death from any cause.
Quality Assessment of Selected Studies
For the quality assessment of studies, we used the same criteria as in our previous meta-analysis. 2 The assessment scheme was based on the Ottawa-Newcastle system and classified into 3 parts: cohort selection, cohort comparability, and outcome (Table 1) . 18 
Statistical Analysis
Meta-analysis was performed with the studies in which either the baseline patient characteristics were comparable or differences were adjusted by appropriate statistical methods. We evaluated the log hazard ratio with 95% CI for included studies and calculated combined hazard ratio and 95% CI by using a random-effects metaanalysis suggested by DerSimonian and Laird. 19 For data analysis, we used R (version 2.15.2) running under Mac OS 10.7. 20 To prepare figures comparing hazard ratios, we used procedure forest plot in package rmeta.
Results
After our initial search of >800 potentially relevant references, 312 studies comparing SIMA and BIMA were assessed for the inclusion criteria of meta-analysis ( Figure 1 ). A total of 9 studies (n=15 583) were selected for meta-analysis (Table 2) . [3] [4] [5] [6] [7] [8] [9] [10] [11] Pair matching was used in 3 studies to create comparable patient groups. [3] [4] [5] Five studies used propensity score methods to provide comparable samples, 2 using propensity score-based patient matching and 3 using quintilebased stratification. 6, 7, [9] [10] [11] Table 3 shows the quality assessment of selected studies. None of the studies was randomized or included a description of unbiased treatment assignment. Five articles reported information about treatment assignment. [5] [6] [7] [8] 10 Although Rankin and colleagues 8 showed a clear principle of patient allocation, with patients allocated prospectively to 2 faculty surgeons with different preferences, the treatment choices were at the discretion of the attending surgeon in the other 4 studies. [5] [6] [7] 10 Four studies had no information on losses to follow-up. 6, 8, 10, 11 Three studies had >1000 patients in both the SIMA and BIMA groups. 6, 7, 9 Lytle and colleagues 6 included 1152 patients in each group after propensity score-based patient matching. The studies of Kurlansky and Stevens, each with >4000 patients, used the propensity score quintile stratification method for analysis. 7, 9 Regarding follow-up, 3 studies by Lytle, Glineur, and Rankin had the longest follow-up duration. 6, 8, 11 The studies of Lytle and Glineur had >15 years of mean follow-up in both the SIMA and BIMA groups. 6, 11 The study by Rankin and colleagues 8 had a median followup duration of 20 years. Although most studies included patients operated on before 2000, the study by Grau and colleagues 10 included patients who had received surgery between 1994 and 2010, reflecting more recent clinical practice.
A meta-analysis of relative survival was performed with 9 studies containing 15 583 patients (8270 SIMA and 7313 BIMA). A significant reduction in mortality by using BIMA was observed by meta-analysis (hazard ratio, 0.79; 95% CI, 0.75-0.84; Figure 2 ). A subgroup analysis considered studies using different statistical approaches: statistically unmatched, [3] [4] [5] 8 quintile-based propensity score analysis, 7, 9, 11 and propensity score-based exact patient matching. 6,10 All 3 subgroups showed a survival benefit of BIMA grafting with hazard ratios of 0.81 (95% CI, 0.69-0.94) in the statistically unmatched group, 0.81 (95% CI, 0.75-0.87) in the quintile-based propensity score analysis group, and 0.75 (95% CI, 0.65-0.85) in the propensity score-based exact matching group. The test for heterogeneity of results was not significant.
Other cardiac-related outcomes such as myocardial infarction, redo surgery, and percutaneous coronary intervention were reported in 6 studies, although they were not considered for meta-analysis because of different reporting patterns (Table 4 ). Six studies reported myocardial infarction as their secondary outcome, 5 of which showed lower incidences of new onset of myocardial infarction in the BIMA group during follow-up. [3] [4] [5] 7, 8 Four studies investigated the incidence of redo surgery, 2 of which reported the benefit of BIMA grafting. 7,8 Table 1 . Quality Assessment of Nonrandomized Studies* Cohort selection was assessed on the answers to 3 questions 1. Were details of criteria for assignment of patients to treatments provided?
(We awarded 1 star for relevant details).
2. How representative was the exposed cohort? (One star if representative of typical patient undergoing CABG; no star if groups of patients were selected or selection of group was not described).
3. How was the nonexposed cohort selected? (One star if drawn from the same community as the exposed cohort; no star if drawn from a different source, or selection of group not described).
Cohort comparability was assessed on the basis of study design or analysis of cohort differences 4. No differences between the 2 groups, or differences controlled for, in particular with reference to age, sex, ventricular function, or diabetic status (2 stars). One star was assigned if 1 of these 4 characteristics was not reported, even if there were no other differences between the groups, and other characteristics had been controlled for. No star was assigned if the 2 groups differed.
Outcome was assessed by 2 criteria 5. Assessment of outcome (1 star for information ascertained by record linkage or interview; no star if this information was not reported or ascertained in some other way). The incidence of percutaneous coronary intervention was presented in 4 studies with no study showing a difference between the 2 groups. 3, [7] [8] [9] Early outcomes were reported in 4 studies (Table 5) . 3, 7, 9, 10 Hospital mortality ranged from 0.6% to 4.6% in the SIMA group and from 0% to 2.6% in the BIMA group. Although 2 studies showed a higher rate of early mortality in the SIMA group, SIMA grafting was not identified as an independent predictor for hospital mortality after adjusted multivariate analysis in both studies. 7, 9 The incidence of sternal infection was presented in 4 studies with no study showing a difference between the 2 groups. 3, 7, 9, 10 
Discussion
This updated systematic review and meta-analysis makes 2 major advances in comparison with our previous report. 2 First, the number of patients in the BIMA group has increased considerably (from 4693 to 7313), now making it more comparable to the SIMA group (n=8270). Second, the duration of follow-up has been extended from a minimum of 4 years to a minimum of 9 years. Our key finding is that BIMA grafting appears to confer a long-term survival benefit in comparison with SIMA grafting after a mean of 9 years of follow-up (hazard ratio, 0.79; 95% CI, 0.75-0.84), and, of note, no studies showed worse outcome in the BIMA grafting.
Our findings are consistent with our previous systematic review that reported a significant reduction in mortality (hazard ratio, 0.81; 95% CI, 0.70-0.94) after a median of 4 years of follow-up with BIMA grafting and with no study showing significantly harmful effect of BIMA grafts. 2 Another meta-analysis from over a decade ago including 16 362 patients from 9 studies also showed a similar survival benefit in the BIMA group (hazard ratio, 0.79; 95% CI, 0.66-0.91). 21 However, our current results are likely to be much more robust and reliable, because that study did not require matching for baseline characteristics, had no minimal follow-up period, and does not include 6 further publications addressing this issue that have appeared over the past decade. [6] [7] [8] [9] [10] [11] The current meta-analysis tried to elongate the follow-up duration by maintaining the previous study's inclusion criteria on patient number and risk factor adjustment.
Long-term follow-up is essential to evaluate the true potential beneficial impact of BIMA grafting. Although studies with relatively short follow-up reported no survival benefit with BIMA grafting, 22 several studies have reported that the survival benefit of BIMA grafting appears to continue to grow through the second decade of follow-up. [3] [4] [5] [6] [7] [8] [9] [10] [11] 23 In particular, Lytle and colleagues 6, 23 reported that the survival advantage of BIMA rather than SIMA grafting continued to diverge out to 20 years after surgery (at 7, 10, 15, and 20 years, respectively, 89% versus 87%, 81% versus 78%, 67% versus 58%, and 50% versus 37%; P<0.0001) and that SIMA grafting was an independent risk factor for mortality in constant-and late-hazard phases but not in the early phase. Likewise, Grau and colleagues 10 reported a 5% survival advantage of BIMA patients at 5 years (96% versus 91%), 10% at 10 years (89% versus 79%), and 18% at 15 years (79% versus 61%). Kurlansky and colleagues [24] [25] [26] also reported favorable results of BIMA use in elderly patients and women and superior long-term survival of BIMA grafting without an increase in operative mortality or morbidity in patients with both normal and reduced cardiac function. Although overall survival was the primary focus of our present study, 6 studies reported secondary outcomes such as myocardial infarction, reoperation, percutaneous coronary intervention, and angina with most suggesting an additional benefit of BIMA grafting on long-term cardiac-related secondary outcomes without evidence of harmful effects. [3] [4] [5] [7] [8] [9] Intuitively, any long-term survival benefit of BIMA grafts is most likely explained by the dramatically superior patency of IMA grafts, as previously discussed, 12 and also by the protective effect that IMA grafts have on atherosclerosis by the increased synthesis of vasodilators such as nitric oxide and the decreased release of vasoconstrictors. 27 In the largest angiographic investigation of right IMA graft patency, Tatoulis and colleagues 12 reported patency rates of 90% in 991 angiograms at a mean of 100 months follow-up. Furthermore, there was no evidence of atheromatous change in the right IMA, and its patencies at 10 years were equivalent to the left IMA for identical coronary territories and always better than those of radial artery or saphenous vein.
Accumulating evidence regarding the advantage of BIMA grafting has influenced the most recent guideline recommendations on surgical revascularization both in Europe (class IA) and the United States (IIaB). 28, 29 Despite such recommendations, however, the use of BIMA grafting in contemporary practice remains disappointingly low. According to the Society of Thoracic Surgeons adult cardiac surgery database in North America, between 1999 and 2009, although the use of a SIMA graft to the left anterior descending coronary artery increased from 87.7% in 2000 to 94·7% in 2009, the use of BIMA grafting increased from 3.5% to only 4.1%. 14 In the United Kingdom and Australia, likewise, only 10% of CABG patients receive 2 arterial grafts (and this may include a radial artery rather than a second IMA graft). 15 Although overall survival was the primary concern in our present study, 6 studies reported secondary outcomes such as myocardial infarction, reoperation, percutaneous coronary intervention, and angina. [3] [4] [5] [7] [8] [9] Six studies reported myocardial infarction as a secondary outcome, 5 of which showed an advantage in the BIMA group. None of the studies with secondary outcomes showed inferior results in the BIMA group, with most reporting benefit of BIMA use. Although not conclusively, we can postulate that most evidence suggests that BIMA grafting appears to have an advantage over SIMA grafting on the long-term cardiac-related secondary outcomes with at least no harmful effects.
The location of the second IMA is indeed an important issue during BIMA grafting. In our series, 4 studies included information about the right IMA locations and other 4 studies had reported the target vessel of the right IMA in their previous reports. In Pick's study, 93% of right IMAs were bypassed to the left coronary artery territory. 4 In other 4 studies, right IMAs were bypassed preferably to the left coronary system. 5, 6, 9, 11 Only 1 study by Naunheim and colleagues 3 used the right IMA for the right coronary artery in all cases. Rankin and colleagues 8 described their graft strategy most clearly. They used 2 IMAs for the 2 largest coronary arteries, which were the left anterior descending artery and left circumflex artery in 62% of patients. As reviewed from our selected articles, the majority of institutions used right IMA for the left coronary territory. Although it has been a prevailing belief that longevity is improved by placing both IMA grafts to the left coronary system, more recently published long-term data also support secondary IMA grafting to the right coronary system. Accordingly, the recently revised US guidelines for CABG included the use of second IMA grafting to the left circumflex artery or right coronary artery (when critically stenosed and perfusing left ventricular myocardium) as a class IIa indication with level of evidence B. 29 Surgeons avoid the use BIMA grafts for various reasons, including increased risk of wound complications, a longer operation time, increased technical demands, lack of randomized trials, and few long-term follow-up studies. 30 In an effort to obtain more reliable evidence, the ART trial randomly assigned 3102 patients to SIMA or BIMA grafting in 27 centers in 8 countries with a primary outcome of 10-year survival. In its interim analyses, 30-day mortality was just 16 The rates of stroke, myocardial infarction, and repeat revascularization (ie, safety end points) were similar at ≈2%, suggesting that the contemporary use of BIMA grafting by appropriately trained surgeons does not increase short-term mortality. Furthermore, the use of a second IMA graft only added 23 minutes to an operation already lasting almost 4 hours. A potentially higher risk of sternal infection or dehiscence is probably the most important potential limitation to BIMA grafting. In the ART trial, the incidence of sternal reconstruction was higher in the BIMA group (SIMA 0.6% versus BIMA 1.9%). The ART trial reflected that the prevalence of diabetes mellitus in the real clinical practice was 24% in both the SIMA and BIMA groups. Diabetes mellitus is one of the strongest predictors of sternal dehiscence, and it is also noteworthy that diabetes mellitus was present in almost 50% of patients with sternal dehiscence. 16 The avoidance of BIMA use in patients with diabetes mellitus (and other recognized risk factors, as well, such as obesity and pulmonary disease) allied to a skeletonization technique during IMA harvesting may significantly reduce the incidence of sternal wound complications. 31, 32 This meta-analysis contained no randomized trials and is subject to the limitations and potential confounding and biases of all observational studies. Of particular relevance, it is known that some surgeons prefer BIMA grafting in lower-risk patients with a greater chance of long-term benefit from CABG. 23 Accordingly, although statistical adjustments attempted to minimize biases in treatment assignment, undefined confounding factors may still exist. Our study has several other limitations. Various perioperative factors that might be related with postoperative patients survival such as ethnicity, pulmonary disease, renal disease, and postoperative complications including mediastinitis were not considered for analysis. Although 4 studies clearly showed that they only included first-time CABG patients, other studies did not clearly demonstrate whether they only included first-time surgery or not. The relatively lower incidence of diabetic patients in our series is another potential bias. Although the inclusion criteria regarding follow-up duration was more than a mean of 9 years for the whole study population, 3 studies showed >1 year difference of follow-up duration between the SIMA and the BIMA groups, 7, 9, 11 which may add another potential bias to our study. Finally, publication bias may have had an influence on the combined results of observational studies.
Nevertheless, the available data in our meta-analysis appears to consistently suggest that BIMA grafting improves long-term survival after CABG in comparison with SIMA grafting; no study showed a detrimental effect. Along with the early results of the ART trial, this meta-analysis supports a much more liberal use of BIMA grafting. 
